Norwegian biotech company Arctic Bioscience (Euronext Growth Oslo:ABS) has entered into an agreement for a new clinical study on psoriasis with its drug candidate HRO350, which is developed from herring roe oil, the company announced on Wednesday.
The three-year agreement with Smerud Medical Research International is worth NOK75m.
The phase IIb study aims to investigate the efficacy and safety of HRO350 and to establish the optimal dose.
More than 500 patients with mild to moderate psoriasis will be recruited in seven countries, including Norway, starting in the first quarter of 2022.
Arctic Bioscience recently raised NOK300m and was listed on the Euronext Growth market in Oslo on 24 February 2021.
(EUR1=NOK10.21)
Eisai and Nuvation Bio report taletrectinib MAA validated by European regulator
Novo Nordisk's Awiqli once-weekly basal insulin treatment approved by US FDA
Kodiak Sciences reports positive Phase 3 results for Zenkuda in diabetic retinopathy
Clarity Pharmaceuticals signs copper-64 manufacturing agreement with Theragenics
Merck to acquire Terns Pharmaceuticals for USD6.7bn
Maze Therapeutics reports positive Phase 2 data for MZE829 in patients with AMKD
Bio-Techne expands COMET spatial biology platform with new SPYRE Panels and Amplification Kits
CRISM Therapeutics advances Phase 2 glioblastoma trial with initial ChemoSeed batch manufactured
Myosin Therapeutics granted USD2m funding from Florida Department of Health
Clover Biopharmaceuticals reports positive US Phase I data for RSV re-vaccination in older adults
Hope Medicine reports first patient dosed in Phase III trial of HMI-115
Akeso's Phase II trials of AK146D1 and AK138D1 approved in China
Insilico Medicine and ASKA Pharmaceutical expand partnership on women's health targets